Literature DB >> 31493246

HOXA11-AS promotes the migration and invasion of hepatocellular carcinoma cells by inhibiting miR-124 expression by binding to EZH2.

Wen-Long Zhang1, Ya-Nan Zhao1, Zhang-Zhen Shi1, Gui-Ying Gu1, Dan Cong1, Chen Wei2, Yuan-Song Bai3.   

Abstract

The objective of this study was to examine the function of the long non-coding RNA (lncRNA) HOXA11-AS in hepatocellular carcinoma (HCC). In total, samples from liver tumor and surrounding normal liver tissues were collected from 66 cases of HCC patients. Normal liver cell line HL-7702 and HCC cell lines HepG2, Hep3B, MHCC-97H and BEL7402 were used. Cells were transfected with different small interference RNAs or vectors. Then, transwell assay, qRT-PCR, CHIP, RIP and Western blot experiments were performed. We found that the HOXA11-AS expression level was higher in HCC samples than surrounding normal liver tissues. And the higher expression level of HOXA11-AS in HCC patients indicated a lower 5-year survival rate. Knockdown of HOXA11-AS in HepG2 and Hep3B cells caused impaired cell invasion and migration abilities. Otherwise, upregulation of HOXA11-AS in MHCC-97H and BEL7402 cells displayed higher invasion and migration capabilities. We also demonstrated that HOXA11-AS could inhibit miR-124 expression by binding to EZH2. Furthermore, overexpression of miR-124 or knockdown EZH2 expression could reverse the HOXA11-AS-induced migration and invasion effects in HCC cells. In summary, the high HOXA11-AS expression in HCC patients is associated with the poor outcome. HOXA11-AS could inhibit miR-124 expression by binding to EZH2 and thus promoted the migration and invasion of HCC cells.

Entities:  

Keywords:  EZH2; HCC; HOXA11-AS; Invasion; Migration; miR-124

Mesh:

Substances:

Year:  2019        PMID: 31493246     DOI: 10.1007/s13577-019-00269-x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  34 in total

1.  DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis.

Authors:  Cong Tan; Fan Qiao; Ping Wei; Yayun Chi; Weige Wang; Shujuan Ni; Qifeng Wang; Tongzhen Chen; Weiqi Sheng; Xiang Du; Lei Wang
Journal:  Mol Carcinog       Date:  2015-02-03       Impact factor: 4.784

2.  Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer.

Authors:  Shibin Qu; Xisheng Yang; Wenjie Song; Wei Sun; Xiaolei Li; Jianlin Wang; Yue Zhong; Runze Shang; Bai Ruan; Zhuochao Zhang; Xuan Zhang; Haimin Li
Journal:  Tumour Biol       Date:  2015-10-19

3.  Protein intake, chronic liver diseases, and hepatocellular carcinoma.

Authors:  Manlio Vinciguerra
Journal:  Hepatology       Date:  2014-09-19       Impact factor: 17.425

4.  Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.

Authors:  Li Liu; Zhibing Xu; Lei Zhong; Hang Wang; Shuai Jiang; Qilai Long; Jiejie Xu; Jianming Guo
Journal:  BJU Int       Date:  2015-04-21       Impact factor: 5.588

Review 5.  Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma.

Authors:  Chen Li; Jing Chen; Kai Zhang; Bing Feng; Rui Wang; Longbang Chen
Journal:  Cell Physiol Biochem       Date:  2015-05-11

6.  The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.

Authors:  Yong Jae Shin; Jeong-Ho Kim
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

7.  Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton.

Authors:  Pernilla von Nandelstadh; Erika Gucciardo; Jouko Lohi; Rui Li; Nami Sugiyama; Olli Carpen; Kaisa Lehti
Journal:  Mol Biol Cell       Date:  2014-07-02       Impact factor: 4.138

8.  A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer.

Authors:  Edward J Richards; Jennifer Permuth-Wey; Yajuan Li; Y Ann Chen; Domenico Coppola; Brett M Reid; Hui-Yi Lin; Jamie K Teer; Andrew Berchuck; Michael J Birrer; Kate Lawrenson; Alvaro N A Monteiro; Joellen M Schildkraut; Ellen L Goode; Simon A Gayther; Thomas A Sellers; Jin Q Cheng
Journal:  Oncotarget       Date:  2015-10-27

Review 9.  Long noncoding RNAs: a potential novel class of cancer biomarkers.

Authors:  Aliaksandr A Yarmishyn; Igor V Kurochkin
Journal:  Front Genet       Date:  2015-04-23       Impact factor: 4.599

10.  Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.

Authors:  Feng Wang; Hou-Qun Ying; Bang-Shun He; Yu-Qin Pan; Qi-Wen Deng; Hui-Ling Sun; Jie Chen; Xian Liu; Shu-Kui Wang
Journal:  Oncotarget       Date:  2015-04-10
View more
  5 in total

1.  The Haoqin-Huaban formula alleviates UVB-induced skin damage through HOXA11-AS-mediated stabilization of EZH2.

Authors:  Xuying Xu; Siyi Wang; Dongmei Zhou; Jianhua Qu; Cang Zhang; Yichuan Xu; Liyun Sun
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 4.060

2.  Long Noncoding RNA HOXA11-AS and Transcription Factor HOXB13 Modulate the Expression of Bone Metastasis-Related Genes in Prostate Cancer.

Authors:  Aya Misawa; Yukihiro Kondo; Hiroyuki Takei; Toshihiro Takizawa
Journal:  Genes (Basel)       Date:  2021-01-27       Impact factor: 4.096

Review 3.  The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Bashdar Mahmud Hussen; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

4.  LINC02476 Promotes the Malignant Phenotype of Hepatocellular Carcinoma by Sponging miR-497 and Increasing HMGA2 Expression.

Authors:  Yuxia Duan; Mengjing Zhao; Mengmeng Jiang; Zhi Li; Caifang Ni
Journal:  Onco Targets Ther       Date:  2020-04-01       Impact factor: 4.147

5.  Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells.

Authors:  Xiaowei Zhong; Siyi Huang; Dianfeng Liu; Ziping Jiang; Qinglong Jin; Chengshun Li; Liu Da; Qunyan Yao; Dongxu Wang
Journal:  Cancer Med       Date:  2020-06-02       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.